Our Technology
A New Class of Medicines – We translate molecular nanomotor biology into first-in-class therapeutics.
We are developing therapies for oncology and central nervous system indications with a platform designed for targeting molecular nanomotor proteins. Our lead programs are specifically tailored to target myosin nanomotor proteins, which play critical roles in a wide range of cellular processes.
A Fundamental
Molecular nanomotors are fundamental to a wide range of diseases, including cancers, vascular diseases, microbial infections, fibrosis, neurodegeneration, and psychiatric disorders. This approach targets a previously untapped superfamily of drug targets that serve critical roles in cell movement, growth, division, and transport.
Dual NMII Inhibition To treat cancer, we developed a family of dual inhibitors of non-muscle myosin IIA and IIB to target the cellular mechanics of tumor cells where conventional signaling-based therapies fall short. Inhibiting these molecular nanomotors has a range of devastating effects on tumor cells, including stopping their invasion and proliferation.
NMIIA
Allows tumor cells to change shape and invade healthy tissue, supporting metastasis. Regulates cell movement by physically moving and reshaping the actin cytoskeleton.
NMIIB
Is the convergent point for cell division, promoting tumor cell proliferation. Regulates cell division in cancer cells.
Targeting the Physical Mechanisms of Aggressive, Drug-Resistant Tumors
Our dual inhibitors of NMIIA and NMIIB offer a first-in-class approach to halting metastasis and proliferation in aggressive, drug-resistant tumors.